NCT05642962 - Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2022

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions

Metastatic Pancreatic Ductal AdenocarcinomaMetastatic Pancreatic CancerMetastatic Pancreatic AdenocarcinomaMetastatic Pancreatic CarcinomaPancreatic CarcinomaPancreatic Carcinoma MetastaticPancreatic Carcinoma Non-resectablePancreatic CancerPancreatic Cancer Non-resectablePancreatic Cancer Stage IVPancreatic Cancer MetastaticPDACPDAC - Pancreatic Ductal Adenocarcinoma

Interventions

DRUG

Pertzye

Treatment with standard dose or higher dose Pancrelipase will continue for 20 weeks from enrollment. Participants will consume assigned blinded weight based Pancrelipase dose concurrent with first bite of every meal and snack for the duration of enrollment.

Trial Locations (7)

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison

11553

Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale

11725

Memorial Sloan Kettering Cancer Center @ Suffolk - Commack (Limited Protocol Activities), Commack

07920

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge

07748

Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown

07645

Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale

All Listed Sponsors

lead

Memorial Sloan Kettering Cancer Center

OTHER